[go: up one dir, main page]

NO20006041L - N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer - Google Patents

N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer

Info

Publication number
NO20006041L
NO20006041L NO20006041A NO20006041A NO20006041L NO 20006041 L NO20006041 L NO 20006041L NO 20006041 A NO20006041 A NO 20006041A NO 20006041 A NO20006041 A NO 20006041A NO 20006041 L NO20006041 L NO 20006041L
Authority
NO
Norway
Prior art keywords
disorders
compounds
drug
disease
piperidylmethylamine
Prior art date
Application number
NO20006041A
Other languages
English (en)
Other versions
NO20006041D0 (no
Inventor
Neil Wishart
Alan Martin Birch
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO20006041D0 publication Critical patent/NO20006041D0/no
Publication of NO20006041L publication Critical patent/NO20006041L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Forbindelser med formel I. omfattende farmasøytisk akseptable salter derav hvor R representerer H eller F, deres fremstilling og anvendelse av dem ved behandling av depresjon, angst, psykoser, Parkinson's sykdom, fedme, hypertensjon, Tourette's syndrom, seksuell dysfunksjon, medikamentavhengighet, medikament-misbruk, kognitive lidelser, Alzheimer's sykdom, senil demens, tvangs-nevrotisk adferd, panikk-anfall, spiseforstyrrelser, anoreksi, kardiovaskulære og cerebrovaskulære lidelser, migrene, ikke-insulinavhengig diabetes mellitus, hyperglykemi, forstoppelse, arrytmi, lidelser i det neuroendocrine system, stress, prostatisk hypertrofi, medikament-fremkalte ekstrapyramidale symptomer eller spastisitet; er beskrevet.
NO20006041A 1998-06-03 2000-11-29 N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer NO20006041L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811879.7A GB9811879D0 (en) 1998-06-03 1998-06-03 Therapeutic agents
PCT/EP1999/003648 WO1999062902A1 (en) 1998-06-03 1999-05-26 N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors

Publications (2)

Publication Number Publication Date
NO20006041D0 NO20006041D0 (no) 2000-11-29
NO20006041L true NO20006041L (no) 2000-11-29

Family

ID=10833098

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006041A NO20006041L (no) 1998-06-03 2000-11-29 N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer

Country Status (20)

Country Link
EP (1) EP1087964A1 (no)
JP (1) JP2002517392A (no)
KR (1) KR20010052526A (no)
CN (1) CN1304408A (no)
AR (1) AR018622A1 (no)
AU (1) AU4369599A (no)
BG (1) BG104988A (no)
BR (1) BR9910927A (no)
CA (1) CA2333756A1 (no)
CO (1) CO5021190A1 (no)
GB (1) GB9811879D0 (no)
HR (1) HRP20010005A2 (no)
HU (1) HUP0102233A2 (no)
ID (1) ID27067A (no)
IL (1) IL139552A0 (no)
NO (1) NO20006041L (no)
PL (1) PL344594A1 (no)
SK (1) SK17602000A3 (no)
TR (1) TR200003569T2 (no)
WO (1) WO1999062902A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915616D0 (en) * 1999-07-05 1999-09-01 Knoll Ag Therapeutic agents
GB0007376D0 (en) * 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
CA2405971C (en) * 2000-05-12 2010-03-30 Solvay Pharmaceuticals B.V. New piperazine and piperidine compounds
JP2003532676A (ja) * 2000-05-12 2003-11-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ＣＮＳ障害を治療するための組合せられたドーパミンＤ２、５−ＨＴ１Ａおよびαアドレノレセプターアゴニスト作用、を有する化合物の使用
CN100540546C (zh) * 2004-05-05 2009-09-16 弗·哈夫曼-拉罗切有限公司 用于调节5-ht6受体、5-ht2a受体或两者的芳基磺酰基苯并二烷
BRPI0608353A2 (pt) 2005-02-17 2009-12-01 Wyeth Corp derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilfundidos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681325B1 (fr) * 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
FR2701479B1 (fr) * 1993-02-11 1995-05-12 Pf Medicament Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique.
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
NO20006041D0 (no) 2000-11-29
GB9811879D0 (en) 1998-07-29
AR018622A1 (es) 2001-11-28
BG104988A (bg) 2001-11-30
AU4369599A (en) 1999-12-20
CN1304408A (zh) 2001-07-18
JP2002517392A (ja) 2002-06-18
IL139552A0 (en) 2002-02-10
EP1087964A1 (en) 2001-04-04
HRP20010005A2 (en) 2001-12-31
PL344594A1 (en) 2001-11-05
WO1999062902A1 (en) 1999-12-09
HUP0102233A2 (hu) 2002-05-29
BR9910927A (pt) 2001-02-20
ID27067A (id) 2001-02-22
KR20010052526A (ko) 2001-06-25
SK17602000A3 (sk) 2001-08-06
CA2333756A1 (en) 1999-12-09
TR200003569T2 (tr) 2001-04-20
CO5021190A1 (es) 2001-03-27

Similar Documents

Publication Publication Date Title
DE69423767D1 (de) 1,4-Benzodioxan-Derivate mit Affinität für D2 Rezeptoren und Nützlichkeit in der Behandlung von Psychosen
AR002830A1 (es) Nuevos compuestos de piperazina sustituida y procedimiento para prepararlos
AU1794097A (en) Tropane-derivatives, their preparation and use
BR0206513A (pt) Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
TWI237023B (en) Benzoxazinone derivatives, their preparation and use
NO20042141L (no) Terapeutiske quinolonforbindelser med 5-HT-antagonistiske egenskaper
WO2004022558A3 (en) Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
NO20006041L (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer
NZ313164A (en) Benzodioxan-2-ylmethyl derivatives substituted by heterocyclyl-carboxamide and medicaments
WO2002085896A8 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
WO2001072741A3 (en) N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders
TR199901478T2 (xx) 5-HT Resept�r aktivitesine sahip olan s�lfonamid bile�ikleri.
JP2007538046A5 (no)
Corbel et al. 1-Benzazepine derivatives acting as ATP-dependent potassium-channels antagonists
NO20051617L (no) Piperidinderivater av heterocyklusfusjonerte benzodioksaner med antidepressiv aktivitet
MX9709509A (es) Agentes terapeuticos.
RU2000133316A (ru) N-бензодиоксанилметил-1-пиперидил-метиламины, обладающие сродством к рецепторам 5-нт
TW421647B (en) (Thiophen-2-yl)-piperidin or tetrahydropyridin azabicyclocarboxamides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application